ConforMIS Inc (NASDAQ:CFMS) Major Shareholder Sells $1,052,934.61 in Stock
ConforMIS Inc (NASDAQ:CFMS) major shareholder Archon Capital Management Llc sold 279,293 shares of the business’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $3.77, for a total value of $1,052,934.61. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Archon Capital Management Llc also recently made the following trade(s):
- On Thursday, July 11th, Archon Capital Management Llc sold 151,022 shares of ConforMIS stock. The shares were sold at an average price of $3.76, for a total value of $567,842.72.
NASDAQ CFMS opened at $3.67 on Friday. The firm has a market cap of $253.13 million, a PE ratio of -4.96 and a beta of 2.30. ConforMIS Inc has a twelve month low of $0.36 and a twelve month high of $4.83. The company has a quick ratio of 2.33, a current ratio of 3.00 and a debt-to-equity ratio of 0.64. The business has a 50-day simple moving average of $4.00.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CFMS. Spark Investment Management LLC raised its holdings in ConforMIS by 172.2% in the 1st quarter. Spark Investment Management LLC now owns 500,000 shares of the medical instruments supplier’s stock worth $1,440,000 after purchasing an additional 316,300 shares during the period. Tibra Equities Europe Ltd acquired a new position in shares of ConforMIS during the first quarter valued at approximately $381,000. Joseph P. Lucia & Associates LLC acquired a new position in shares of ConforMIS during the first quarter valued at approximately $45,100,000. Creative Planning raised its holdings in shares of ConforMIS by 133.8% during the first quarter. Creative Planning now owns 116,922 shares of the medical instruments supplier’s stock valued at $337,000 after acquiring an additional 66,922 shares during the last quarter. Finally, CAPROCK Group Inc. raised its holdings in shares of ConforMIS by 300.0% during the first quarter. CAPROCK Group Inc. now owns 80,000 shares of the medical instruments supplier’s stock valued at $230,000 after acquiring an additional 60,000 shares during the last quarter. 34.11% of the stock is owned by institutional investors.
Several brokerages have recently issued reports on CFMS. BidaskClub cut Xperi from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 19th. Zacks Investment Research raised HB Fuller from a “sell” rating to a “hold” rating in a report on Wednesday, July 3rd. ValuEngine raised Vistra Energy from a “hold” rating to a “buy” rating in a report on Wednesday, July 3rd. BTIG Research upped their price target on Yum! Brands to $114.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. Finally, Oppenheimer reduced their price target on Littelfuse from $215.00 to $210.00 and set an “outperform” rating for the company in a report on Thursday, May 2nd. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $3.40.
Conformis, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee.
Featured Article: Bear Market – How and Why They Occur
Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.